Table 1.
Baseline characteristics of Brazilian COVID-19 hemodialysis patients (N = 741)
| All | Fatal course | P value | ||
|---|---|---|---|---|
| No N = 602 |
Yes N = 139 |
|||
| Age, years | 57 ± 16 | 55 ± 16 | 64 ± 15 | < 0.001 |
| Male gender | 452 (61.0) | 364 (60.9) | 88 (63.3) | 0.528 |
| Obesity (body mass index ≥ 30 kg/m2) | 129 (17.4) | 105 (17.6) | 24 (17.3) | 0.958 |
| Comorbidities | ||||
| Previous stroke | 26 (3.5) | 16 (2.7) | 10 (7.2) | 0.009 |
| Chronic liver disease | 15 (2.0) | 13 (2.2) | 2 (1.4) | 0.587 |
| Diabetes mellitus | 293 (39.5) | 216 (35.9) | 77 (55.4) | < 0.001 |
| Hypertension | 619 (83.5) | 498 (82.7) | 121 (87.1) | 0.215 |
| Chronic obstructive pulmonary disease | 27 (3.6) | 17 (2.8) | 10 (7.2) | 0.013 |
| Peripheral arterial obstructive disease | 53 (7.2) | 42(7.0) | 11 (7.9) | 0.699 |
| Heart failure | 129 (17.4) | 100 (16.6) | 29 (20.9) | 0.233 |
| Previous myocardial infarction | 41 (5.5) | 31 (5.1) | 10 (7.2) | 0.342 |
| Previous kidney transplantation | 35 (4.7) | 28 (5.1) | 7 (7.4) | 0.880 |
| Previous or current neoplasia | 27 (3.6) | 21 (3.5) | 6 (4.3) | 0.639 |
| Positive HIV serology | 4 (0.5) | 3 (0.5) | 1 (0.7) | 0.748 |
| Current smoking | 14 (1.9) | 13 (2.2) | 1 (0.7) | 0.261 |
| Former smoking | 49 (6.6) | 38 (6.3) | 11 (7.9) | 0.493 |
| Use of RAAS inhibitors | 310 (46.1) | 250 (45.4) | 60 (49.6) | 0.400 |
| Dialysis aspects | ||||
| Central venous catheter | 186 (25.1) | 133 (22.1) | 53 (38.1) | < 0.001 |
| Funding by the Public Health System | 620 (83.7) | 511 (84.9) | 109 (79.0) | 0.090 |
| Private management | 579 (78.1) | 464 (77.1) | 115 (82.7) | 0.262 |
Values are mean ± SD or n (%)
RAAS renin–angiotensin–aldosterone system